TABLE 2

Biodistribution of 89Zr-Labeled Panitumumab in Selected Organs of Female Athymic (NCr) nu/nu Mice Bearing Pulmonary Metastatic Human LS-174T Tumors

Tissue1 d2 d3 d5 d5 d (block)*
Blood19.77 ± 0.0611.11 ± 0.736.32 ± 1.413.70 ± 0.4214.11 ± 3.44
Tumor59.95 ± 3.1578.05 ± 7.1560.12 ± 6.9461.97 ± 6.0211.61 ± 1.26
Liver7.64 ± 0.536.13 ± 0.8813.64 ± 6.738.67 ± 0.816.81 ± 0.72
Spleen5.71 ± 0.204.63 ± 0.455.68 ± 0.455.91 ± 1.435.39 ± 1.28
Kidney4.27 ± 0.323.46 ± 0.132.97 ± 0.603.00 ± 0.223.57 ± 0.41
Lung13.86 ± 1.149.60 ± 1.367.69 ± 1.428.56 ± 2.315.07 ± 1.14
Heart4.92 ± 0.313.56 ± 0.292.67 ± 0.551.64 ± 0.084.50 ± 0.53
Femur3.60 ± 0.184.04 ± 0.145.07 ± 0.576.40 ± 0.963.51 ± 1.03
Tumor/blood3.03 ± 0.157.09 ± 0.6411.07 ± 1.7917.26 ± 2.050.91 ± 0.17
  • * Receptor-blocking studies were performed by coinjecting 0.1 mg of panitumumab with radiolabeled antibody.

  • Biodistribution data were obtained at 1, 2, 3, and 5 d after intravenous injection of 89Zr-labeled panitumumab. All values are expressed as %ID/g (except ratios). Data represent mean value ± SEM from at least 4 determinations.